je.st
news
Eisai to Present New Research on Oncology Products and Pipeline at 50th Asco Annual Meeting
2014-05-15 07:54:39| Logistics - Topix.net
Highlights Include New Phase Iii Clinical Data on Investigational Anticancer Agent Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer Tokyo, May 15, 2014 - - Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results on Halaven and lenvatinib with a novel binding mode) will be presented during the 50th ... (more)
Tags: products
research
present
meeting
Category:Transportation and Logistics